Journal Article

Allergen Peptides, Recombinant Allergens and Hypoallergens for Allergen-Specific Immunotherapy

Marth, Katharina, Focke-Tejkl, Margarete, Valenta, Rudolf, Niederberger, Verena, Lupinek, Christian

2014

Overview

Opinion statement Allergic diseases are among the most common health issues worldwide. Specific immunotherapy has remained the only disease-modifying treatment, but it is not effective in all patients and may cause side effects. Over the last 25 years, allergen molecules from most prevalent allergen sources have been isolated and produced as recombinant proteins. Not only are these molecules useful in improved allergy diagnosis, but they also have the potential to revolutionize the treatment of allergic disease by means of immunotherapy. Panels of unmodified recombinant allergens have already been shown to effectively replace natural allergen extracts in therapy. Through genetic engineering, several molecules have been designed with modified immunological properties. Hypoallergens have been produced that have reduced IgE binding capacity but retained T cell reactivity and T cell peptides which stimulate allergen-specific T cells, and these have already been investigated in clinical trials. New vaccines have been recently created with both reduced IgE and T cell reactivity but retained ability to induce protective allergen-specific IgG antibodies. The latter approach works by fusing per se non-IgE reactive peptides derived from IgE binding sites of the allergens to a virus protein, which acts as a carrier and provides the T-cell help necessary for immune stimulation and protective antibody production. In this review, we will highlight the different novel approaches for immunotherapy and will report on prior and ongoing clinical studies.

• Publisher: Springer International Publishing,Springer Nature B.V
• Subject: Allergens / Allergic diseases / Allergies / Allergology / Antibodies / Asthma / Binding sites / Clinical trials / Cytokines / Disease / Family Medicine / General Practice / Genetic engineering / Immunoglobulin E / Immunoglobulin G / Immunotherapy / Lymphocytes / Lymphocytes T / Medicine / Medicine & Public Health / Patients / Peptides / Proteins / Rhinitis / Section Editor / Specific Immunotherapy (L Cox / Specific Immunotherapy (L Cox, Section Editor) / Vaccines